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Chromosomal microarrayAbstract We report on the molecular detection of two microduplications involving chromosomes
Xp21.1–Xp21.2 and 17p12 in a 35-year-old female with clinical phenotype of Charcot–Marie–
Tooth disease type 1A (CMT1A) documented by chromosomal microarray analysis. The 17p12
microduplication was approximately 1.32 Mb in size and contained eleven genes including the
peripheral myelin protein 22 (PMP22), while the Xp21.1–Xp21.2 microduplication was estimated
to be 626 Kb in size and contained part of the dystrophin (DMD) gene. Constitutional interstitial
microduplication of 17p12 segment encompassing the PMP22 gene has been reported in individuals
with Charcot–Marie–Tooth disease type 1A. Defects in the DMD gene (deletion, duplication, or
mutation) are associated with Duchenne and Becker muscular dystrophies (DMD and BMD).
Combined microduplications of Xp21/DMD with 17p12/PMP22 are extremely rare with only
one published report of a male patient with changes in both the DMD and PMP22 genes.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Charcot–Marie–Tooth disease type 1A (CMT1A) and Duch-
enne muscular dystrophy (DMD) are neurogenetic conditions
with variable and distinct phenotypes. CMT1A is a demyelin-
ating peripheral neuropathy inherited in an autosomal domi-
nant manner. Clinical features include progressive peripheral
200 A. Sidhu et al.motor and sensory neuropathy, pes cavus, peroneal muscle
atrophy, inability to walk on the heels, deep tendon areﬂexia
and distal sensory disturbance with slow nerve conduction
velocity [1]. CMT1A is a slow progressive disease with age of
onset from 5 to 25 years. About 70–80% of CMT1A cases
are due to microduplication of about 1.4 Mb in the short
arm of chromosome 17p12 region that includes the peripheral
myelin protein gene (PMP22; OMIM# 601097) [2–6].
DMD is an X-linked recessive disorder caused by muta-
tions in the DMD gene located on Xp21 region with an inci-
dence in males of 1 in 3500. The clinical phenotype includes
a spectrum of disorders. On the mild end of the spectrum,
symptoms include asymptomatic increase in serum creatine
kinase (CK) concentration, myoglobinuria, and isolated quad-
riceps myopathy. The other end of the spectrum includes
DMD-associated dilated cardiomyopathy without evidence
of skeletal muscle disease, Becker muscular dystrophy
(BMD), and the most severe form, DMD [7]. Women are usu-
ally asymptomatic carriers but can develop muscle weakness
and cardiac abnormalities [8]. Clinical features of DMD
include progressive symmetric muscle weakness more in the
proximal muscles than distal, absence of sensory symptoms,
speech delay, delayed motor milestones, with wheelchair
dependency in most boys before age 13 years. Molecular etiol-
ogies for DMD include deletions of one or more exons (60–
70%), point mutations (25–35%), and microduplications [9].
Co-occurrence of an Xp21 microduplication encompassing
the DMD locus in conjunction with a 17p12/PMP22 microdu-
plication is extremely rare with only one published report of a
male patient with changes in both the DMD and PMP22 genes
[10]. Here, we describe the second patient with combined
microduplication of the Xp21.1–21.2 region including part of
DMD gene and the 17p12 region including the PMP22 gene
identiﬁed by chromosomal microarray in a female with clinical
phenotype of CMT1A.
2. Clinical report
We report on a 35-year-old right-handed Caucasian female
who came for an initial evaluation to the CMT clinic at our
hospital. She was noted to have hypotonia and club feet at
birth. She gave a history of delayed motor milestones, multiple
knee surgeries, high arched feet, and back pain. At age 16 years
she was diagnosed with CMT1A based on clinical signs and
nerve conduction velocity (NCV) study. She reported worsen-
ing of symptoms over the last year with inability to perform
ﬁne motor tasks with her hands, pain in the upper extremities
upon holding her son up, and decreased sensation and motor
function of ankles and toes. Physical examination showed nor-
mal cognition, absent reﬂexes bilaterally, bilateral atrophy of
thenar eminence, hammertoes, pes cavus, with decreased
power at the wrist and intrinsic hand muscles, ankle and toes.
There was decreased sensation to vibration and pin-prick, with
absent joint position sense up to the wrists and ankles bilater-
ally. NCV evaluation showed evidence of demyelinating neu-
ropathy. Her serum CK level was within normal limits.
The patient reported to have two healthy daughters aged 3
and 6, and a 4 year-old son recently diagnosed with DMD
(microduplication of dystrophin gene exons 45–61). Her son
presented with hypotonia at birth, delayed motor milestones
with walking at 18-months, speech delay, elevated CK level,and calf pseudohypertrophy. Family history was signiﬁcant
for distal limb atrophy and weakness in the patient’s brother,
father, paternal aunt, and paternal grandfather (Fig. 1). At the
present time, none of the symptomatic individuals had a
molecular diagnosis for CMT1A. There was no known con-
sanguinity and no known family history of muscle weakness,
delayed milestones, cardiomyopathy, or sensory symptoms
other than what is mentioned above.
3. Materials and methods
3.1. Chromosomal microarray
Genomic DNA was isolated from the patient peripheral blood
using the Puregene kit (Gentra Systems, Minneapolis, MN).
Chromosomal microarray using an oligonucleotide + single
nucleotide polymorphism based microarray containing 180K-
features (SurePrint G3 GGXChip + SNP v1.0 4x180k manu-
factured by Agilent Technologies, Santa Clara, California)
was performed according to the manufacturer’s protocol.
The microarray slide was scanned on an Agilent G2565 CA
microarray scanner system. Data were extracted from the
microarray image; the background subtracted, and then nor-
malized using Agilent Cytogenomics software (v2.5.8.1). Data
were imported into array CGH Analytics Software (Geno-
glyphix; Signature Genomic Laboratories, Spokane, WA).
The array design and genomic coordinates are based on NCBI
build 37 (hg19).
3.2. Fluorescent in situ hybridization (FISH)
FISHwas performed onmetaphase and interphase cells derived
from the PHA-stimulated peripheral blood from the patient
using BAC probes from the duplicated 17p12 region and the
duplicated Xp21.1–p21.2 region. For the duplicated 17p12
region BAC probe RP11-849N15 (HG18 chr17:15,037,103-
15,270,554) was used and the RP11-599B13 probe (HG18
chr17:7,849,167-8,045,204) from the 17p13.1 region distal to
the duplicated region was used as a control. For the duplicated
Xp21.1–p21.2 region BAC probe RP11-1083A21 (HG18
chrX:31,354,660-31,533,379) was used and the RP11-141B6
probe (HG18 chrX:57,316,603-57,480,676) from the Xp11.1
region proximal to the duplicated region was used as a control.
The hybridization and posthybridization washes were per-
formed according to standard protocol. Blood samples from
other relatives were not available for FISH or microarray
analysis.4. Results
Chromosomal microarray detected a 1.32 Mb microduplica-
tion/copy number gain involving chromosome 17p12 short
arm region (Fig. 2A). The duplicated region contains at least
eleven genes including the peripheral myelin protein 22
(PMP22). The 17p microduplication was conﬁrmed by FISH
analysis using the RP11-849N15 probe (Fig. 2B). In addition,
microarray also detected a 626 Kb microduplication/copy gain
involving chromosome Xp21.1–Xp21.2 short arm region
including part of the dystrophin gene (DMD) (Fig. 3A). The
Xp21.1–Xp21.2 microduplication was conﬁrmed by FISH
3 yrs6 yrs 4 yrs
35 yrs
22 yrs
42 yrs 39 yrs
Figure 1 The family pedigree. Family history showed that the CMT1A was most likely inherited from the paternal side of the family.
The proband (marked with arrow), her brother, father, paternal aunt and paternal grandfather exhibited phenotypic features of CMT1A
(shaded in blue). DMD microduplication (shaded in red) was passed from the proband to her son, age 4 years. The green shaded area
indicates molecular conﬁrmation for 17p12/PMP22 microduplication. Empty squares indicate unaffected males, empty circles unaffected
females.
DMD carrier female with CMT1A 201analysis using the RP11-1083A21 (Fig. 3B). Additional FISH
or CMA testing on at risk family members was recommended
to determine whether the microduplications were inherited or
de novo, but was not performed due to lack of availability
and the age of the children.
5. Discussion
CMT1A and DMD are inherited neuromuscular disorders
with distinct clinical features. The combination of both
CMT1A and DMD has been described in only one patient
in the literature, a male who showed characteristics of both
the disorders [10]. The PMP22 microduplication and frame-
shift mutation in the DMD gene were both inherited from
his mother. His phenotypic presentation included features of
both peripheral neuropathy and muscular dystrophy. His
mother exhibited a CMT1A phenotype. We present the second
case of a female patient who was found to have changes in
genes responsible for both conditions. Chromosomal micro-
array was performed due to her clinical features, strong family
history of CMT1A and the recent diagnosis of her son with
DMD. Though molecular conﬁrmation has not been made
for any other family members due to lack of familial availabil-
ity and the age of the children, the CMT1A microduplication
appears to be coming from the paternal side of the family
based on reported symptoms. It is unknown if the proband’s
mother is a carrier for the DMD microduplication althoughthe risk may be decreased since neither her brother nor her
three maternal uncles demonstrate any symptoms of DMD.
Clinically, DMD can be distinguished from CMT1A by
complete lack of sensory symptoms, normal nerve conduction
velocity, proximal muscle weakness and wasting versus distal
in CMT1A, calf pseudohypertrophy, elevated serum creatine
kinase, speech delay, classic Gower maneuver (use of distal
muscles to rise from a squatting position) and dilated cardio-
myopathy. Motor milestones delayed at 6 months with later
manifestations of bilateral pes cavus, absent deep tendon
reﬂexes, and sensory loss are indicative of CMT1A. Upon
review of literature, Charcot–Marie–Tooth neuropathies in
association with various forms of muscular dystrophy have
been reported in four cases [10–13]. Buteﬁsch et al. ﬁrst
reported on a 22-year-old female who inherited both facio-
scapulohumeral muscular dystrophy (FSHD) and CMT1A
from each of her parents leading to shortened life span and
early death [11]. The second report is of a 27-year-old male
who inherited the X-linked Charcot–Marie–Tooth disease
from his mother caused by a mutation in the connexin32 gene
and acquired a de novo in-frame deletion in his DMD gene
leading to a milder form, BMD [12]. His clinical course was
changed with severe proximal and distal muscle wasting and
rapid progression of both the diseases. Recent publication by
Schreiber et al. [13] describes a 53-year-old male with both
CMT1A and FSHD mutations presenting with an atypical
phenotype. There is one further report similar to our case on
Figure 2 Analysis of 17p12 region encompassing the PMP22 gene. (A) CMA oligonucleotide data plot for chromosome 17 depicting a
1.32 Mb microduplication (shaded in pink) of the 17p12 region including the PMP22 gene region (circled in red). (B) FISH image showing
microduplication of 17p12 region on the interphase cell. Clone RP11-849N15 from the 17p12 region was labeled in orange and RP11-
599B13 clone from the 17p13.1 region was labeled in green as a control. The three orange signals present on the interphase cells indicate
microduplication of the 17p12 region.
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[10]. Vondracek et al. reported a male patient who inherited
the CMT1A/PMP22 microduplication and frameshift muta-
tion in the DMD gene from his mother [10]. Within the scope
of the published report by Vondracek et al. we can deduce that
the mother of the proband showed phenotype similar to our
patient with features of CMT1A. To the best of our knowl-
edge, our case is the second report of combined changes in
both the DMD and PMP22 genes and the ﬁfth case describing
two alterations on different chromosomes involving unrelated
neuromuscular diseases in the same patient.Our patient demonstrates clinical signs and symptoms of
CMT1A with a signiﬁcant family history. Her chromosomal
microarray results showed that she passed on the DMD micro-
duplication to her 4-year-old son who presented with high
serum CK, speech delay, and the classic Gower maneuver on
examination. Interestingly, the ﬁnding of delayed milestones
with hypotonia at birth for her son makes it highly likely that
he may carry the CMT1A/PMP22 microduplication although
it would be somewhat early presentation. Based on his risk, her
son should be monitored for symptoms of CMT1A until
molecular testing for the 17p12 microduplication is performed.
Figure 3 Analysis of the Xp21 region encompassing part of the DMD gene. (A) CMA oligonucleotide data plot for the X chromosome
depicting a 626 Kb microduplication (shaded in pink) of the Xp21.1–Xp21.2 region including part of the DMD gene region (circled in
red). (B) FISH image showing microduplication of the Xp21 region on the interphase cell. Clone RP11-1083A21 from the Xp21 region
was labeled in orange and RP11-141B6 clone from the Xp11.1 region was labeled in green as a control. The three orange signals present on
the interphase cells indicate microduplication of the Xp21 region.
DMD carrier female with CMT1A 203His phenotype would be different from our proband’s since he
would have the disadvantage of a severe manifestation due to
both the DMD and CMT1A mutations. Our patient was
offered molecular FISH or chromosomal microarray testing
for her other family members but additional testing was
declined.
This report demonstrates two alterations on different chro-
mosomes involving unrelated neuromuscular diseases in thesame patient and adds to the present information for this rare
occurrence. Literature evidence shows alteration of disease
course with worse prognosis in the presence of Charcot–
Marie–Tooth neuropathy and a muscular dystrophy
[10,11,13]. Hence even if a mutation in a disease gene has been
detected, further genetic testing may be warranted in unusual
clinical presentations. Given the unusual phenotype of our
patient’s son not explained by DMD alone, we highly suspect
204 A. Sidhu et al.him to carry the maternal CMT1A microduplication and hope
that the family might re-consider molecular testing. We expect
our patient to be protected from an alteration in clinical course
of CMT1A despite the presence of her DMD microduplication
carrier status (likely due to subtle differences in X inactivation
patterns). However, diligent follow up evaluations would elu-
cidate the natural course of the combination of the two mic-
roduplications in a female.
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